Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report
Abstract Background Primary squamous cell carcinoma of the thyroid is a very rare malignancy with aggressive growth and poor prognosis. There is currently no consensus for treatment modality, however, most patients with primary squamous cell carcinoma of the thyroid are treated with surgery and adju...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-10-01
|
| Series: | Journal of Medical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13256-022-03596-0 |
| _version_ | 1817979589821988864 |
|---|---|
| author | Meng-Lun Hsieh Brian M. Besch Jo Elle G. Peterson Christina Henson |
| author_facet | Meng-Lun Hsieh Brian M. Besch Jo Elle G. Peterson Christina Henson |
| author_sort | Meng-Lun Hsieh |
| collection | DOAJ |
| description | Abstract Background Primary squamous cell carcinoma of the thyroid is a very rare malignancy with aggressive growth and poor prognosis. There is currently no consensus for treatment modality, however, most patients with primary squamous cell carcinoma of the thyroid are treated with surgery and adjuvant chemoradiation. Case presentation We report a rare case of primary squamous cell carcinoma of the thyroid in a 68-year-old White male who underwent chemoradiation and palliative immunotherapy after declining surgery. He was treated with intensity-modulated radiation therapy to 70 Gy in 35 fractions, with concurrent carboplatin–paclitaxel and palliative pembrolizumab. Local thyroid disease recurrence occurred at 6 months post-chemoradiation, and the patient died at 16 months post-chemoradiation. Conclusions This is the first case report demonstrating the use of pembrolizumab as palliative therapy for primary squamous cell carcinoma of the thyroid. Our study also highlights the importance of chemoradiation in decreasing primary mass size and immunotherapy in preventing metastatic disease progression. |
| first_indexed | 2024-04-13T22:44:37Z |
| format | Article |
| id | doaj.art-6474531a589344a389e620d5f22de87e |
| institution | Directory Open Access Journal |
| issn | 1752-1947 |
| language | English |
| last_indexed | 2024-04-13T22:44:37Z |
| publishDate | 2022-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Medical Case Reports |
| spelling | doaj.art-6474531a589344a389e620d5f22de87e2022-12-22T02:26:28ZengBMCJournal of Medical Case Reports1752-19472022-10-011611810.1186/s13256-022-03596-0Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case reportMeng-Lun Hsieh0Brian M. Besch1Jo Elle G. Peterson2Christina Henson3Department of Radiation Oncology, University of Oklahoma Health Sciences CenterDepartment of Pathology, University of Oklahoma Health Sciences CenterDepartment of Pathology, University of Oklahoma Health Sciences CenterDepartment of Radiation Oncology, University of Oklahoma Health Sciences CenterAbstract Background Primary squamous cell carcinoma of the thyroid is a very rare malignancy with aggressive growth and poor prognosis. There is currently no consensus for treatment modality, however, most patients with primary squamous cell carcinoma of the thyroid are treated with surgery and adjuvant chemoradiation. Case presentation We report a rare case of primary squamous cell carcinoma of the thyroid in a 68-year-old White male who underwent chemoradiation and palliative immunotherapy after declining surgery. He was treated with intensity-modulated radiation therapy to 70 Gy in 35 fractions, with concurrent carboplatin–paclitaxel and palliative pembrolizumab. Local thyroid disease recurrence occurred at 6 months post-chemoradiation, and the patient died at 16 months post-chemoradiation. Conclusions This is the first case report demonstrating the use of pembrolizumab as palliative therapy for primary squamous cell carcinoma of the thyroid. Our study also highlights the importance of chemoradiation in decreasing primary mass size and immunotherapy in preventing metastatic disease progression.https://doi.org/10.1186/s13256-022-03596-0Primary squamous cell carcinomaThyroidCase reportImmunotherapyPembrolizumab |
| spellingShingle | Meng-Lun Hsieh Brian M. Besch Jo Elle G. Peterson Christina Henson Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report Journal of Medical Case Reports Primary squamous cell carcinoma Thyroid Case report Immunotherapy Pembrolizumab |
| title | Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report |
| title_full | Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report |
| title_fullStr | Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report |
| title_full_unstemmed | Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report |
| title_short | Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report |
| title_sort | primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy a case report |
| topic | Primary squamous cell carcinoma Thyroid Case report Immunotherapy Pembrolizumab |
| url | https://doi.org/10.1186/s13256-022-03596-0 |
| work_keys_str_mv | AT menglunhsieh primarysquamouscellcarcinomaofthethyroidtreatedwithconcurrentchemoradiationandpalliativeimmunotherapyacasereport AT brianmbesch primarysquamouscellcarcinomaofthethyroidtreatedwithconcurrentchemoradiationandpalliativeimmunotherapyacasereport AT joellegpeterson primarysquamouscellcarcinomaofthethyroidtreatedwithconcurrentchemoradiationandpalliativeimmunotherapyacasereport AT christinahenson primarysquamouscellcarcinomaofthethyroidtreatedwithconcurrentchemoradiationandpalliativeimmunotherapyacasereport |